DrugCite
Search

GAMMAGARD

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Gammagard Adverse Events Reported to the FDA Over Time

How are Gammagard adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Gammagard, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Gammagard is flagged as the suspect drug causing the adverse event.

Most Common Gammagard Adverse Events Reported to the FDA

What are the most common Gammagard adverse events reported to the FDA?

Chills
524 (4.15%)
Pyrexia
448 (3.55%)
Headache
421 (3.33%)
Dyspnoea
349 (2.76%)
Nausea
323 (2.56%)
Vomiting
223 (1.76%)
Urticaria
216 (1.71%)
Back Pain
177 (1.4%)
Tachycardia
176 (1.39%)
Malaise
162 (1.28%)
Rash
154 (1.22%)
Show More Show More
Hypersensitivity
153 (1.21%)
Blood Pressure Increased
148 (1.17%)
Erythema
140 (1.11%)
Hypertension
140 (1.11%)
Infusion Related Reaction
134 (1.06%)
Pruritus
125 (.99%)
Death
122 (.97%)
Fatigue
122 (.97%)
Meningitis Aseptic
121 (.96%)
Anaphylactic Reaction
117 (.93%)
Chest Pain
115 (.91%)
Tremor
114 (.9%)
Dizziness
107 (.85%)
Haemolysis
101 (.8%)
Oxygen Saturation Decreased
100 (.79%)
Hypotension
98 (.78%)
Cough
88 (.7%)
Myocardial Infarction
88 (.7%)
Abdominal Pain
85 (.67%)
Cyanosis
85 (.67%)
Pulmonary Embolism
84 (.66%)
Diarrhoea
80 (.63%)
Pain In Extremity
80 (.63%)
Drug Intolerance
79 (.63%)
Blood Pressure Decreased
78 (.62%)
Cerebrovascular Accident
76 (.6%)
Pneumonia
73 (.58%)
Deep Vein Thrombosis
72 (.57%)
Flushing
72 (.57%)
Asthenia
67 (.53%)
Pain
67 (.53%)
Anxiety
66 (.52%)
Chest Discomfort
66 (.52%)
Anaphylactoid Reaction
65 (.51%)
Drug Exposure During Pregnancy
64 (.51%)
Haemolytic Anaemia
64 (.51%)
Hepatitis C
62 (.49%)
Hyperhidrosis
62 (.49%)
Body Temperature Increased
61 (.48%)
Condition Aggravated
59 (.47%)
Feeling Cold
58 (.46%)
Meningitis
56 (.44%)
Oedema Peripheral
54 (.43%)
Hepatitis B
53 (.42%)
Hypoxia
53 (.42%)
Muscle Spasms
53 (.42%)
Neck Pain
53 (.42%)
Convulsion
52 (.41%)
Musculoskeletal Stiffness
52 (.41%)
Pallor
51 (.4%)
Arthralgia
50 (.4%)
Therapeutic Product Ineffective For...
50 (.4%)
Abdominal Pain Upper
49 (.39%)
Feeling Abnormal
49 (.39%)
Heart Rate Increased
49 (.39%)
Somnolence
49 (.39%)
Drug Ineffective
47 (.37%)
Paraesthesia
46 (.36%)
Influenza Like Illness
44 (.35%)
Myalgia
44 (.35%)
Anaphylactic Shock
43 (.34%)
Haemoglobin Decreased
42 (.33%)
Musculoskeletal Pain
42 (.33%)
Anti-erythrocyte Antibody Positive
41 (.32%)
Blister
38 (.3%)
Respiratory Failure
38 (.3%)
Sepsis
37 (.29%)
Loss Of Consciousness
36 (.28%)
Photophobia
36 (.28%)
Hypoaesthesia
35 (.28%)
Dehydration
34 (.27%)
Wheezing
34 (.27%)
Cold Sweat
33 (.26%)
Syncope
33 (.26%)
Vision Blurred
33 (.26%)
Livedo Reticularis
31 (.25%)
Hepatitis B Antibody Positive
29 (.23%)
Unresponsive To Stimuli
29 (.23%)
Abdominal Distension
28 (.22%)
Bronchospasm
28 (.22%)
Sinusitis
28 (.22%)
Feeling Hot
26 (.21%)
Tachypnoea
25 (.2%)
Throat Tightness
25 (.2%)
Agitation
24 (.19%)
Atrial Fibrillation
24 (.19%)
Aphasia
23 (.18%)
Lip Swelling
23 (.18%)
Off Label Use
23 (.18%)
Renal Failure
23 (.18%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Gammagard, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Gammagard is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Gammagard

What are the most common Gammagard adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Gammagard, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Gammagard is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Gammagard According to Those Reporting Adverse Events

Why are people taking Gammagard, according to those reporting adverse events to the FDA?

Off Label Use
412
Product Used For Unknown Indication
275
Immunodeficiency Common Variable
236
Hypogammaglobulinaemia
206
Drug Use For Unknown Indication
191
Immunodeficiency
163
Show More Show More
Primary Immunodeficiency Syndrome
152
Chronic Inflammatory Demyelinating ...
122
Myasthenia Gravis
85
Kawasakis Disease
60
Multiple Sclerosis
59
Idiopathic Thrombocytopenic Purpura
55
Guillain-barre Syndrome
55
Secondary Immunodeficiency
54
Multifocal Motor Neuropathy
40
Chronic Lymphocytic Leukaemia
32
Polymyositis
31
Demyelinating Polyneuropathy
30
Dementia Alzheimers Type
28
Dermatomyositis
27
Thrombocytopenia
26
Selective Igg Subclass Deficiency
25
Blood Immunoglobulin G Decreased
25
Polyneuropathy
24
Selective Iga Immunodeficiency
19
Neuropathy Peripheral
18
Multiple Myeloma
18
Combined Immunodeficiency
16
Intentional Drug Misuse
16
Immunoglobulin Therapy
15
Wegeners Granulomatosis
13
Immune System Disorder
12
Bone Marrow Transplant
12
Blood Immunoglobulin A Decreased
11
Sepsis
11
Infection
11
Myasthenic Syndrome
11
Autoimmune Thrombocytopenia
10
Brutons Agammaglobulinaemia
10
Autoimmune Disorder
10
Systemic Lupus Erythematosus
10
Non-hodgkins Lymphoma
10
Pemphigus
10
Leukaemia
8
Waldenstroms Macroglobulinaemia
8
Drug Exposure During Pregnancy
8
Immunoglobulins Decreased
8
Neuropathy
8
Congenital Hypogammaglobulinaemia
8
Thrombocytopenic Purpura
7
Rheumatoid Arthritis
7

Drug Labels

LabelLabelerEffective
Gammagard S/dBaxter Healthcare Corporation17-JUN-11
Gammagard S/dBaxter Healthcare Corporation17-JUN-11
Gammagard S/dBaxter Healthcare Corporation17-JUN-11
Gammagard LiquidBaxter Healthcare Corporation22-JUL-11
Gammagards/dBaxter Healthcare Corporation16-DEC-11
Gammagards/dBaxter Healthcare Corporation16-DEC-11
Gammagards/dBaxter Healthcare Corporation16-DEC-11
Gammagards/dBaxter Healthcare Corporation03-SEP-12
Gammagards/dBaxter Healthcare Corporation03-SEP-12

Gammagard Case Reports

What Gammagard safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Gammagard. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Gammagard.